Zacks Research Estimates Haemonetics’ Q1 Earnings (NYSE:HAE)

Haemonetics Corporation (NYSE:HAE) – Equities research analysts at Zacks Research cut their Q1 2027 EPS estimates for shares of Haemonetics in a research note issued to investors on Monday, September 8th. Zacks Research analyst Team now forecasts that the medical instruments supplier will earn $1.19 per share for the quarter, down from their prior estimate of $1.20. The consensus estimate for Haemonetics’ current full-year earnings is $4.55 per share. Zacks Research also issued estimates for Haemonetics’ FY2027 earnings at $5.23 EPS.

Other equities research analysts also recently issued research reports about the stock. Robert W. Baird initiated coverage on shares of Haemonetics in a research report on Thursday, June 26th. They set an “outperform” rating and a $87.00 price objective for the company. Wall Street Zen downgraded shares of Haemonetics from a “buy” rating to a “hold” rating in a research report on Tuesday, May 13th. Barrington Research lowered their price objective on shares of Haemonetics from $95.00 to $86.00 and set an “outperform” rating for the company in a research report on Friday, August 8th. JPMorgan Chase & Co. reaffirmed a “neutral” rating and set a $62.00 price objective (down previously from $85.00) on shares of Haemonetics in a research report on Friday, August 8th. Finally, Baird R W raised shares of Haemonetics to a “strong-buy” rating in a research report on Wednesday, June 25th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $82.50.

Haemonetics Price Performance

Shares of NYSE:HAE opened at $54.16 on Tuesday. The company has a quick ratio of 1.04, a current ratio of 1.72 and a debt-to-equity ratio of 1.04. Haemonetics has a fifty-two week low of $50.68 and a fifty-two week high of $94.99. The firm has a 50-day simple moving average of $65.18 and a 200 day simple moving average of $65.63. The company has a market cap of $2.61 billion, a PE ratio of 16.56, a P/E/G ratio of 1.00 and a beta of 0.39.

Haemonetics (NYSE:HAE) last issued its earnings results on Thursday, August 7th. The medical instruments supplier reported $1.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.01 by $0.09. The business had revenue of $321.39 million for the quarter, compared to analyst estimates of $305.12 million. Haemonetics had a net margin of 12.14% and a return on equity of 26.64%. The company’s revenue for the quarter was down 4.4% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.02 EPS. Haemonetics has set its FY 2026 guidance at 4.700-5.00 EPS.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of HAE. Norges Bank bought a new position in Haemonetics in the 2nd quarter worth about $36,822,000. SG Capital Management LLC lifted its stake in shares of Haemonetics by 92.5% in the 2nd quarter. SG Capital Management LLC now owns 906,892 shares of the medical instruments supplier’s stock worth $67,663,000 after acquiring an additional 435,660 shares during the period. Citigroup Inc. lifted its stake in shares of Haemonetics by 87.3% in the 1st quarter. Citigroup Inc. now owns 625,565 shares of the medical instruments supplier’s stock worth $39,755,000 after acquiring an additional 291,574 shares during the period. AQR Capital Management LLC lifted its stake in shares of Haemonetics by 157.9% in the 2nd quarter. AQR Capital Management LLC now owns 450,248 shares of the medical instruments supplier’s stock worth $33,390,000 after acquiring an additional 275,683 shares during the period. Finally, River Road Asset Management LLC lifted its stake in shares of Haemonetics by 18.7% in the 2nd quarter. River Road Asset Management LLC now owns 1,655,676 shares of the medical instruments supplier’s stock worth $122,586,000 after acquiring an additional 260,624 shares during the period. Institutional investors own 99.67% of the company’s stock.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.